Reproductive-focused patient monitoring developer Ava said today it raised $30 million in a Series B round of funding to support its cycle-tracking sensor bracelet.
The majority of the financing in the round came from existing investors, the Switzerland-based company said, and was joined by European VC firm Btov and SVC Ltd.
The company’s flagship device is the Ava bracelet which uses sensor technology to monitor a woman’s menstrual cycle or pregnancy in real time. Ava is currently engaged in clinical studies of the device and its sensor technology with hopes of using its algorithms as a non-hormonal contraceptive device.
“It’s exciting to work with a company that is literally reshaping the way we think about menstrual cycles, hormones and women’s health. Combining the best in science, data insights and technology is not only helping to create families, but improving women’s lives around the world,” Brigitte Leeners of the University Hospital of Zurich said in a press release.
Funds from the financing round will help support further product research and development as the company looks to enhance existing products and explore new applications.
“Ava’s long-term vision is to accompany women through all stages of their reproductive life by providing data-driven, clinically proven technology that will make a woman’s life easier, healthier and better — be it when they just want to understand their body, while they are trying to prevent pregnancy, trying to get pregnant, are pregnant or entering menopause,” Ava co-founder Pascal Koenig said in a prepared statement.